Basics

BMI Calculator: What Your Number Means for GLP-1 Eligibility and Weight Loss

GLP-1 Companion · 7 min read

Quick answer

Use the BMI calculator to get the screening number most GLP-1 providers and insurers still ask for. Then use that number to decide whether to talk to a clinician or compare licensed partner options.

A BMI calculator is not a diagnosis and it is not a prescription. It is the first gate most GLP-1 providers, insurers, and telehealth intake forms still use. If your number is near 27 or 30, the next decision is not "should I buy medication online?" It is "what licensed clinician or program can evaluate me properly?"

My position: BMI is a blunt tool, but it is still commercially important because it determines whether you should move from research to provider comparison. If you may qualify, use /partners to compare legitimate access paths before paying a program fee or uploading medical details.

What Is BMI?

BMI is calculated by dividing your weight in kilograms by your height in meters squared (kg/m²). In imperial units, the formula is: weight (lbs) × 703 ÷ height (inches)². The result falls into one of four standard categories.

Below 18.5 — Underweight: May indicate insufficient body fat; associated with nutritional deficiencies and other health risks.
18.5 to 24.9 — Normal weight: Generally associated with the lowest health risks in population-level studies.
25.0 to 29.9 — Overweight: Elevated risk for type 2 diabetes, hypertension, and cardiovascular disease.
30.0 and above — Obesity: Significantly elevated risk for metabolic and cardiovascular conditions. Obesity is further classified as Class 1 (30–34.9), Class 2 (35–39.9), and Class 3 / severe obesity (40+).

BMI Thresholds for GLP-1 Medication Eligibility

The FDA has approved GLP-1 medications for weight management in adults who meet specific BMI criteria. Understanding these thresholds helps you assess whether you may qualify for a prescription.

BMI ≥ 30 (obesity): Eligible for GLP-1 weight loss medications (Wegovy, Zepbound) regardless of other health conditions.
BMI ≥ 27 with at least one weight-related comorbidity: Eligible even without reaching the obesity threshold. Qualifying conditions include type 2 diabetes, high blood pressure (hypertension), high cholesterol (dyslipidemia), obstructive sleep apnea, and cardiovascular disease.
BMI ≥ 27 (lower threshold for some indications): Ozempic and Mounjaro are primarily prescribed for type 2 diabetes — BMI is one factor, but diabetes diagnosis is the primary criterion.
Below 27: GLP-1 medications are generally not approved or prescribed for weight management below this threshold.

What Weight Loss Can You Expect on GLP-1 Medications?

GLP-1 medications produce clinically meaningful weight loss in most patients, with results from landmark trials:

Wegovy (semaglutide 2.4 mg): Average of 14.9% body weight loss over 68 weeks in the STEP 1 trial.
Zepbound (tirzepatide 15 mg): Average of 22.5% body weight loss over 72 weeks in the SURMOUNT-1 trial.
Ozempic (semaglutide 1–2 mg): Average of 4–7 kg over 40–104 weeks in diabetes trials.
Results vary significantly by individual — genetics, adherence, lifestyle factors, and dose all play a role.

The Limitations of BMI

BMI is a useful population-level screening tool, but it has well-documented limitations that medical professionals increasingly acknowledge:

Does Not Measure Body Fat Directly

BMI measures total weight relative to height — it cannot distinguish between fat mass and muscle mass. A highly muscular athlete may have a BMI in the "overweight" range while having very low body fat. Conversely, an individual with low muscle mass and high body fat ("skinny fat" or normal-weight obesity) may have a normal BMI despite significant metabolic risk.

Does Not Account for Fat Distribution

Where fat is stored matters greatly for health risk. Visceral fat (stored around internal organs, measured by waist circumference) is far more metabolically harmful than subcutaneous fat (stored under the skin). Two people with identical BMIs can have very different health risks depending on their fat distribution.

Racial and Ethnic Differences

The standard BMI thresholds were derived from predominantly European populations. Research has shown that people of Asian descent have higher metabolic risk at lower BMI levels — the WHO has proposed adjusted thresholds (overweight at BMI ≥ 23, obesity at BMI ≥ 27.5) for Asian populations. Conversely, people of certain African descent groups may have higher muscle mass at equivalent BMIs, potentially leading to overclassification of obesity risk.

Does Not Capture Age-Related Changes

As we age, we typically lose muscle mass and gain fat mass — a process that can occur without significant changes in BMI. This means BMI may underestimate metabolic risk in older adults.

Better Measures of Metabolic Health

For a more complete picture of your metabolic health and GLP-1 medication candidacy, doctors typically look beyond BMI:

Waist circumference: High risk is defined as ≥ 40 inches (102 cm) in men and ≥ 35 inches (88 cm) in women.
Waist-to-height ratio: Considered one of the best simple predictors of cardiometabolic risk; a ratio above 0.5 indicates elevated risk.
Fasting blood glucose and HbA1c: For identifying prediabetes and type 2 diabetes.
Fasting lipid panel: Evaluates cardiovascular risk independent of BMI.
Blood pressure: Hypertension is a qualifying comorbidity for GLP-1 eligibility at BMI ≥ 27.
DEXA scan or BIA: Can directly measure body fat percentage and lean mass, though not routinely used in clinical practice.

Next Steps If Your BMI Suggests Eligibility

If your BMI falls in the range that may qualify you for GLP-1 medication, the next step is a conversation with a healthcare provider — primary care physician, endocrinologist, obesity medicine specialist, or a licensed telehealth provider. They should review your full health history, order relevant labs when appropriate, discuss benefits and risks, and determine whether a GLP-1 medication is appropriate for you specifically.